These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 39131433)

  • 1. Actinium-225 in Targeted Alpha Therapy.
    Rahman AKMR; Babu MH; Ovi MK; Zilani MM; Eithu IS; Chakraborty A
    J Med Phys; 2024; 49(2):137-147. PubMed ID: 39131433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Innovations and Nano-Delivery of Actinium-225: A Narrative Review.
    Mdanda S; Ngema LM; Mdlophane A; Sathekge MM; Zeevaart JR
    Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of recent advancements in Actinium-225 labeled compounds and biomolecules for therapeutic purposes.
    Hassan M; Bokhari TH; Lodhi NA; Khosa MK; Usman M
    Chem Biol Drug Des; 2023 Nov; 102(5):1276-1292. PubMed ID: 37715360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Actinium-225 targeted alpha particle therapy for prostate cancer.
    Bidkar AP; Zerefa L; Yadav S; VanBrocklin HF; Flavell RR
    Theranostics; 2024; 14(7):2969-2992. PubMed ID: 38773983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes.
    Morgenstern A; Bruchertseifer F; Apostolidis C
    Curr Radiopharm; 2012 Jul; 5(3):221-7. PubMed ID: 22642390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supply and Clinical Application of Actinium-225 and Bismuth-213.
    Morgenstern A; Apostolidis C; Bruchertseifer F
    Semin Nucl Med; 2020 Mar; 50(2):119-123. PubMed ID: 32172796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Evaluation of a Macrocyclic Actinium-225 Chelator, Quality Control and In Vivo Evaluation of
    Yang H; Zhang C; Yuan Z; Rodriguez-Rodriguez C; Robertson A; Radchenko V; Perron R; Gendron D; Causey P; Gao F; Bénard F; Schaffer P
    Chemistry; 2020 Sep; 26(50):11435-11440. PubMed ID: 32588455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of a thorium/actinium generator at the Canadian Nuclear Laboratories.
    Perron R; Gendron D; Causey PW
    Appl Radiat Isot; 2020 Oct; 164():109262. PubMed ID: 32819503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Overview of Targeted Alpha Therapy with
    Morgenstern A; Apostolidis C; Kratochwil C; Sathekge M; Krolicki L; Bruchertseifer F
    Curr Radiopharm; 2018; 11(3):200-208. PubMed ID: 29732998
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Koniar H; Wharton L; Ingham A; Rodríguez-Rodríguez C; Kunz P; Radchenko V; Yang H; Rahmim A; Uribe C; Schaffer P
    Phys Med Biol; 2024 Jul; 69(15):. PubMed ID: 38925140
    [No Abstract]   [Full Text] [Related]  

  • 11. Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications.
    Miederer M; Scheinberg DA; McDevitt MR
    Adv Drug Deliv Rev; 2008 Sep; 60(12):1371-82. PubMed ID: 18514364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of
    Dumond ARS; Rodnick ME; Piert MR; Scott PJH
    Curr Radiopharm; 2022; 15(2):96-103. PubMed ID: 34250876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiopharmaceutical Quality Control Considerations for Accelerator-Produced Actinium Therapies.
    Abou DS; Zerkel P; Robben J; McLaughlin M; Hazlehurst T; Morse D; Wadas TJ; Pandya DN; Oyama R; Gaehle G; Nickels ML; Thorek DLJ
    Cancer Biother Radiopharm; 2022 Jun; 37(5):355-363. PubMed ID: 35695807
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications.
    Nelson BJB; Andersson JD; Wuest F
    Pharmaceutics; 2020 Dec; 13(1):. PubMed ID: 33396374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production of actinium-225 for alpha particle mediated radioimmunotherapy.
    Boll RA; Malkemus D; Mirzadeh S
    Appl Radiat Isot; 2005 May; 62(5):667-79. PubMed ID: 15763472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy.
    Graf F; Fahrer J; Maus S; Morgenstern A; Bruchertseifer F; Venkatachalam S; Fottner C; Weber MM; Huelsenbeck J; Schreckenberger M; Kaina B; Miederer M
    PLoS One; 2014; 9(2):e88239. PubMed ID: 24516620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Actinium-225 Labeled Minigastrin Analogue [
    Qin Y; Imobersteg S; Blanc A; Frank S; Schibli R; Béhé MP; Grzmil M
    Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33198403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of Ac-225 from Th-229 for targeted alpha therapy.
    Apostolidis C; Molinet R; Rasmussen G; Morgenstern A
    Anal Chem; 2005 Oct; 77(19):6288-91. PubMed ID: 16194090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiolabeling of a polypeptide polymer for intratumoral delivery of alpha-particle emitter,
    Shalgunov V; Engudar G; Bohrmann L; Wharton L; Maskell K; Johann K; Barz M; Schaffer P; Herth MM; Radchenko V
    Nucl Med Biol; 2022; 104-105():11-21. PubMed ID: 34839209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted actinium-225 in vivo generators for therapy of ovarian cancer.
    Borchardt PE; Yuan RR; Miederer M; McDevitt MR; Scheinberg DA
    Cancer Res; 2003 Aug; 63(16):5084-90. PubMed ID: 12941838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.